| Autor: |
Osborne, D., Frost, L., Tobal, K., Yin, J. A. Liu |
| Předmět: |
|
| Zdroj: |
Bone Marrow Transplantation; Jul2005, Vol. 36 Issue 1, p67-70, 4p |
| Abstrakt: |
Summary:Relapse postautograft in acute myeloid leukaemia (AML), may in part arise from leukaemia cells present in the bone marrow (BM) inoculum, and the level of minimal residual disease (MRD) in BM harvests used for autografting may therefore be clinically important.We have used the WT1 transcript as a marker of MRD, which was quantitated by RQ-PCR, in the BM harvests of 24 patients receiving an ABMT for AML. ABL was used as a control gene with WT1 level being normalised to 105 copies of ABL per sample. Median WT1 level was 651 copies (range=113–32 700) for the 13 patients with relapse-free survival (RFS) of less than 5 years, and 174 (range=0–1900) for patients with RFS of over 5 years postautograft (P<0.04). The RFS was 10.5 months for patients with WT1 level of >2000 copies (n=5), and has not yet been reached for patients with WT1 level<2000 (n=21), at a median follow-up of 92 months (P<0.05). We show that elevated levels of MRD in BM harvests are associated with a higher relapse risk in patients autografted for AML.Bone Marrow Transplantation (2005) 36, 67–70. doi:10.1038/sj.bmt.1704992 Published online 23 May 2005 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
